...
首页> 外文期刊>The British journal of psychiatry : >Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis
【24h】

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis

机译:安非他酮戒烟和减少精神分裂症的疗效和安全性:系统评价和荟萃分析

获取原文
           

摘要

Background The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain. Aims To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia. Method Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia. Results Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 months (RR = 2.78, P = 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy ( P = 0.002) but not at 6 months ( P = 0.37). There was no significant difference in positive ( P = 0.28) or negative symptoms ( P = 0.49) between the bupropion and the placebo group. Conclusions Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.
机译:背景技术安非他酮作为精神分裂症戒烟辅助的利弊仍不确定。目的总结安非他酮作为精神分裂症烟碱依赖性治疗的有效性和安全性的现有证据。方法对安非他酮与安慰剂或其他治疗控制对精神分裂症成年吸烟者进行比较的随机对照试验(RCT)的系统评价和随机效果荟萃分析。结果包括来自七个RCT的21个报告。在结束治疗后(风险比(RR)= 2.57,P = 0.004)和在6个月时(RR = 2.78,P = 0.05),经安非他酮经生化检查自我报告的戒烟率显着高于安慰剂。安非他酮在治疗结束时的一氧化碳水平显着降低(P = 0.002),但在6个月时未降低(P = 0.37)。安非他酮和安慰剂组在阳性(P = 0.28)或阴性(P = 0.49)症状方面无显着差异。结论安非他酮可提高精神分裂症吸烟者的戒烟率,而不会损害其精神状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号